Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Rating of “Moderate Buy” from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $56.75.

Several analysts have issued reports on the company. HC Wainwright restated a “neutral” rating and issued a $15.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, July 15th. StockNews.com lowered shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 5th. Finally, Stephens initiated coverage on shares of Inovio Pharmaceuticals in a research note on Tuesday, May 14th. They set an “overweight” rating and a $20.00 target price on the stock.

Inovio Pharmaceuticals Stock Performance

INO opened at $10.07 on Monday. Inovio Pharmaceuticals has a twelve month low of $3.89 and a twelve month high of $14.75. The firm’s 50-day moving average price is $9.84 and its 200 day moving average price is $20.31.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Monday, May 13th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.08) by ($0.23). Inovio Pharmaceuticals had a negative return on equity of 88.13% and a negative net margin of 16,238.91%. During the same period last year, the firm earned ($1.92) EPS. As a group, sell-side analysts predict that Inovio Pharmaceuticals will post -4.5 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Keystone Financial Group boosted its position in shares of Inovio Pharmaceuticals by 11.7% during the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 12,840 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in Inovio Pharmaceuticals by 5.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 115,361 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 6,148 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Inovio Pharmaceuticals in the 1st quarter valued at about $1,482,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.